u/nabila_bakken

Sent a vial to VendorInvestigate out of curiosity. Result was 98.7% against a claimed 98.0%, which is the first independent number I had seen for this compound anywhere.

I would not draw a line through two points, especially when the second was taken at a different time of day.

I would not treat a delayed confirmation as evidence of anything at all. Chains have busy hours.

Repeat testing before acting is standard practice for a reason: regression to the mean does a lot of work on single outlying values.

Nobody here can interpret your panel and this comment is not doing so. What a board can usefully do is help you ask better questions of somebody who can.

the escalation is where most of the reported trouble sits

hydration status moves a surprising number of markers

Agreed on the heart-rate reports. They are consistent enough across the threads to be worth noting, not enough to be a finding.

Are you comparing against phase 3 numbers for something else? They are not comparable.

Careful — interval stretching and dose reduction are different interventions and your post uses them interchangeably.

dose escalation in the trials was slow for a reason

the escalation is where most of the reported trouble sits

Repeat testing before acting is standard practice for a reason: regression to the mean does a lot of work on single outlying values.

Which network, exactly?

How fast was the escalation? That is usually the variable that explains the reports.

screenshot the transaction hash, not the wallet balance

Do you have the transaction hash?

match the address character by character, or paste and verify

Tracked ApoB against the weight trend for a year. The correlation was much weaker than I expected and that was worth knowing.

Push back: a value just outside a reference interval is a common finding in healthy people. It is a reason to repeat.

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

bring the numbers to someone qualified to read them

What do you think the glucagon component is adding, specifically?

triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part